semaglutide fda approval date weight loss US approves drug Wegovy to prevent cardiovascular events FDA-Approved Oral Semaglutide Pills for

Human or veterinary use is strictly prohibited under this research use designation

Feeding behavior during long-term hexarelin administration in young and old rats

Linear SOD, GSH, and MDA concentrations were calculated according to this equation

Clinical trial, 48 weeks: Body weight: -24.2% average Fat loss: significant Lean muscle mass: PRESERVED Metabolic markers: dramatically improved Heres why this is different: Ozempic/Mounjaro = dual agonists (GLP-1 + GIP) Suppress appetite You eat less Lose weight but also muscle Retatrutide = adds glucagon receptor Suppresses appetite AND Activates fat burning directly Body uses fat for fuel instead of breaking down muscle Blood work improvements tracked in trials: Fasting glucose: normalized Triglycerides: -40% Inflammatory markers: reduced Insulin sensitivity: significantly improved The metabolic difference: Dual agonists: Force you to eat less (suffer through hunger, lose muscle) Retatrutide: Reprograms metabolism to PREFER burning fat (appetite controlled, muscle preserved) DEXA scans in the study confirmed: Fat mass dropped dramatically